Cipla to distribute Sanofi's CNS product line in India
Sanofi India and Sanofi Healthcare India Private Limited, and Cipla on Tuesday announced an exclusive distribution and marketing partnership for the sale and promotion of Sanofi India's Central Nervous System (CNS) product line in India on March 26, according to an exchange filing.
As part of this collaboration, Cipla will handle the distribution of Sanofi India's six CNS brands, including the industry-leading Frisium brand of anti-epileptic drugs.
According to the joint statement, Cipla will utilise its skills and solid India-wide network of distributors, institutions and market outreach programmes to expand access to these treatments for patients.
Meanwhile, Sanofi India will continue to own, import, and manufacture its entire range of CNS products across plants in India and abroad.
(You can now subscribe to our Economic Times WhatsApp channel)
. Read more on economictimes.indiatimes.com
